FDA Reinstates NMN for Supplements: Medspas Eye Synergy with NAD+ Therapy and GLP-1 Symptom Relief

The FDA has reversed its previous decision, making NMN legal again as a dietary supplement and expanding options for those interested in wellness and longevity.
The FDA has reversed its previous decision, making NMN legal again as a dietary supplement and expanding options for those interested in wellness and longevity.
Courtesy of mizina At Adobe Stock

In 2022, the FDA decided to revoke Nicotinamide Mononucleotide (NMN) from being marketed as a dietary supplement, declaring it needed to first undergo investigation as a new drug. On Sept. 29, three years later, however, the FDA amended its decision and ruled the drug as lawful to use in dietary supplements. Because this is a direct precursor, compared to other NAD+ precursors that must first be converted to NMN inside the cell to become NAD+, patients could see these supplements paired with the medical-grade NAD+ therapies they receive at medspas, and potentially alongside GLP-1 use.  

This article is only available to registered users.

Log In to View the Full Article

More in Home